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Wemodeled nevirapine (NVP) pharmacokinetics in HIV-infectedMalawian patients to assess the relationship between drug
exposure and patient characteristics, genetic polymorphisms, and development of hypersensitivity reaction (HSR). One thou-
sand one hundred seventeen patients were prospectively recruited and followed for 26 weeks with multiple or single serum sam-
ples obtained in a subset of patients for NVP quantification. Single nucleotide polymorphisms (SNPs) within CYP2B6 and
CYP3A4 genes were typed. Nonlinear mixed effects modeling was utilized to assess the influence of patient characteristics and
host genetics on NVP apparent oral clearance (CL/F) and to explore the relationship between NVP CL/F and HSR. Published
haplotype distributions were used to simulate NVP concentrations in Caucasians versus Africans. One hundred eighty patients
(101 female) were included in the model; 25 experienced HSR. No associations between patient demographics or HSR and NVP
CL/F were evident. A significant relationship between CYP2B6 c.983T>C and CYP2B6 c.516G>T and NVP CL/F was observed
(P< 0.01). NVP CL/F was reduced by 23% and 36% in patients with CYP2B6 983TT/516TT and 983TC/516GG or GT, respec-
tively, compared to the reference genotype. Simulated exposures suggested similar proportions (13 to 17%) of patients with sub-
therapeutic NVP among Caucasians and an African population. Influence of CYP2B6 polymorphisms on NVP CL/F in this popu-
lation is in agreement with other reports. Our data indicate a lack of association between NVP exposure and HSR. Based on these
data, dose optimization based solely on ethnicity (without individual gene testing) is unlikely to impact on risk of treatment fail-
ure or toxicity even in an African population with high carriage of poor metabolizer mutations.
Sub-Saharan Africa remains the region of the world most af-fected by HIV infection and is home to approximately two-
thirds of all people living with HIV (1). In Malawi, antiretroviral
therapy (ART) has been scaled up to reach nearly half a million
individuals (http://www.hivunitmohmw.org/). Here, as in most
other national ART programs in sub-Saharan Africa, a public
health approach has been deployed to maximize health gains for
the population. Most individuals (90%) receiving ART are on
first-line, nevirapine (NVP)-containing regimens and are man-
aged using a combination of clinical monitoring and symptom-
driven laboratory observations.
Between 6 and 10% of patients receiving NVP develop cutane-
ous eruptions or liver injury, which can sometimes be severe and
occasionally fatal (2, 3). The risk of such hypersensitivity reactions
(HSRs) in African patients remains poorly characterized andmay
differ from those of cohorts in developed countries because na-
tional andWHOpolicies allow initiation of NVP-based therapy at
higher CD4 counts. The relationship between drug exposure and
development of NVP HSR is unclear, but previous studies have
reported higher plasma drug exposures in black African and Thai
patients (4) and higher rates of liver toxicity in patients receiving
once-daily NVP than in those receiving twice-daily NVP, presum-
ably due to highermaximum concentrations attained after dosing
(5).
NVP is metabolized by cytochrome P450 enzymes CYP3A4
and CYP2B6 (6). Single nucleotide polymorphisms (SNPs) in the
genes encoding both enzymes have been shown to impact NVP
pharmacokinetics in various populations (7–9). In addition,
CYP3A5 (which shares 90% substrate specificity with CYP3A4) is
more commonly expressed in African populations andmay influ-
ence NVP exposure. We have previously reported an association
between CYP2B6 polymorphisms and body weight with NVP
plasma exposure in patients recruited in the United Kingdom and
Germany (10). These pharmacogenetic influences carry potential
implications for dose optimization, management of drug-drug
interactions, “forgiveness” formissed doses, and choice of partner
drugs for coformulation. Individualized genetic testing is rarely
feasible in resource-limited settings.However, if pharmacogenetic
information can be used to ensure that the dosing and design of
regimens and treatment policy are optimized for populations
rather than for individuals, considerable public health benefitmay
accrue.
In this study, we sought to characterizeNVP pharmacokinetics
in a Malawian population receiving ART. A modeling approach
was utilized to assess associations between individual factors (in-
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cluding multiple genetic influences across different loci as well as
nongenetic covariates) and NVP plasma exposure and also exam-
ined the relationship between exposure and the subsequent devel-
opment of drug hypersensitivity. Finally, through the implemen-
tation of mathematical simulations we aimed to evaluate the
hypothesis that pharmacogenetic information can be utilized to
optimize NVP dosing for populations without the requirement
for individual genetic testing.
MATERIALS AND METHODS
Patients. Between March 2007 and September 2008, 1,117 HIV-infected
antiretroviral treatment-naive patients starting on NVP-based therapy
were prospectively recruited at the Queen Elizabeth Central Hospital,
Blantyre, Malawi, and followed for 26 weeks. The study received full eth-
ical approval from the Liverpool School of Tropical Medicine Research
Ethics Committee (Liverpool, United Kingdom) and the College of Med-
icine Research and Ethics Committee, University of Malawi (Blantyre,
Malawi). All patients gave their written informed consent. Patients re-
ceived nevirapine at a dose of 200 mg twice daily (200 mg once daily
within the first 2 weeks of therapy; lead-in dose) as part of a generic
combination tablet formulation also containing lamivudine and stavu-
dine. Inclusion criteria for the study were age greater than 16 years, ability
to give informed consent, WHO staging visit performed in the antiretro-
viral (ARV) clinic, and ability to attend all study visits for 6 months.
Patients were started on ART if they were WHO clinical stage III or IV
and/or their CD4 cell count was250 cells/mm3. Patients were excluded
if they were jaundiced at baseline, taking concomitant tuberculosis treat-
ment or hepatotoxic drugs, or currently pregnant or if they had received
previous antiretroviral therapy. Patients who did not adhere to the study
protocol, transferred to district centers outside the Blantyre catchment
area, or had poor compliance with treatment (i.e., missed10 tablets per
month) were withdrawn from the study.
A diagnosis of NVP hypersensitivity was made if NVP treatment was
discontinued and any of the followingwere observed: (i) rash (widespread
maculopapular rash without systemic manifestations and getting worse
on treatment continuation), (ii) hypersensitivity syndrome (widespread
rash and systemic manifestations such as fever, cough, or abnormal liver
function tests [LFT]), (iii) Stevens-Johnson syndrome (SJS), (iv) toxic
epidermal necrolysis (TEN), or (v) drug-induced liver injury manifesting
with jaundice. In all cases, the temporal relationship between drug initia-
tion and the occurrence of the reaction, the effect of drug cessation, and
the possibility of other possible causes was assessed. The AIDS Clinical
Trials Group (ACTG) grading for LFT and rash severity (11) and the
Naranjo method for estimating the causality of the adverse reaction (12)
were used. The treating clinician first made the diagnosis of hypersensi-
tivity in relation to NVP intake, and an independent assessment was then
made by a dermatologist.
Pharmacokinetic sampling and drug analysis. Amixture of rich and
sparse pharmacokinetic sampling was performed in a subset of patients.
For NVP-tolerant patients included in the rich sampling subset (n 40,
20 female), drug intake was directly observed and timed on the day of
sampling and administered under fed conditions followed by blood sam-
pling predose (0 h) and 1, 2, 5, and 9 h postdose. Patients willing to give
more blood samples and remain at the clinic for a longer period of time
were selected for the rich sampling subset. For those undergoing random
sampling during clinic visits (n  140), 1 sample per patient was taken,
and if hypersensitivity developed later in the study, a second sampling
event was undertaken. Venous blood samples (10 ml) were drawn, and
serumwas isolated within 2 h of collection and then stored (70°C) until
being shipped to Liverpool, United Kingdom, for drug analysis.
Serum NVP concentrations were quantified by a fully validated high-
pressure liquid chromatography–tandemmass spectrometry (HPLC-MS/
MS) method modified from that reported by Else et al. (13). The lower
limit of quantificationwas 0.518mg/liter, and the assaywas linear up to 10
mg/literwith a precision and bias of10%.The laboratory participated in
an external quality assurance program (International Interlaboratory
Quality Control Program for Therapeutic Drug Monitoring in HIV In-
fection, Nijmegen, The Netherlands) with an acceptable performance.
Genotype analysis.DNAwas extracted from whole blood using a salt
precipitation protocol (14). SNPs within the CYP2B6 and CYP3A5 genes
were typed using the matrix-assisted laser desorption ionization–time of
flight (MALDI-TOF)-based Sequenom iPLEX system (Sequenom Inc.,
San Diego, CA, USA) according to the manufacturer’s protocol. Se-
quence-specific PCR and extended-reaction oligonucleotides were ob-
tained from Metabion GmbH (Martinsried, Germany). Multiplex assays
were designed using the software available from Sequenom. Additionally,
theCYP2B6 c.785AG (rs2279343) polymorphism of CYP2B6was geno-
typed using anAssays-by-DesignTaqMan SNPgenotyping assay (Applied
Biosystems, Foster City, CA, USA).
PCRmixtures (10l) consisted of 1 TaqManUniversal PCRmaster
mix (Applied Biosystems), 1 assay mix (unlabeled PCR primers and
TaqMan minor groove binding [MGB]), probes (6-carboxyfluorescein
[FAM] and VIC labeled), and 20 ng DNA. PCR was performed using an
Applied Biosystems 7700 real-time PCR system (Applied Biosystems).
The following cycling conditionswere used: 95°C for 1min followed by 40
cycles of 92°C for 15 s and 60°C for 1 min. Allelic discrimination analysis
and genotype calls were made with the ABI 7700 sequence detection sys-
tem (Applied Biosystems).
Data analysis. Nonlinear mixed effects modeling was applied
(NONMEM version VI 2.0, level 1.1, double precision; Icon Development
Solutions, Ellicott City,MD,USA) (15) using first-order conditional estima-
tion with interaction (FOCE-I). Model fit was assessed by statistical and
graphicalmethods. Theminimal objective function value (OFV; equal to2
log likelihood)wasusedas agoodness-of-fitdiagnosticwithadecreaseof 3.84
points corresponding to a statistically significant difference between hierar-
chical models (P  0.05, 	2 distribution, 1 degree of freedom). Graphical
diagnostics were generated with Microsoft Office Excel 2007 for Windows
(Microsoft Corporation, Redmond, WA, USA). Standard errors of the esti-
mates were determined with the COVARIANCE option, and individual
Bayesian parameter and concentration estimates were determined by the
POSTHOC option.
Pharmacokinetic and covariatemodel building.One- and two-com-
partment models with first- or zero-order absorption without and with
lag time were assessed to determine the best structural model to fit the
data. To describe residual variability proportional, additive and combined
proportional-additive error models were evaluated.
Covariates that could potentially influence NVP pharmacokinetics,
including age, body weight, bodymass index (BMI), sex, hypersensitivity,
CD4 cell count, and viral hepatitis were investigated in the model. As well
as linearly, BMI and CD4 cell count were stratified categorically by their
cutoffs of BMI of  or 18.5 kg/m2 and CD4 of  or 250 cells/mm3.
For continuous variables (e.g., body weight), plots of covariates versus
individual predicted pharmacokinetic parameters were performed to de-
termine possible relationships. Each covariate was introduced separately
and retained only if inclusion in the model produced a statistically signif-
icant decrease in OFV of 3.84 (P  0.05) and was biologically plausible.
Once all relevant covariates were included, a backwards elimination step
was performed and covariates were retained if removal from the model
produced a significant increase in OFV (6.63 points; P  0.01, 	2 dis-
tribution, 1 degree of freedom).
Pharmacogenetic model building. SNPs considered for inclusion
into the genetic model were CYP3A5*6 (SNP1), CYP3A5*3 (SNP2),
CYP2B6 c.983TC (SNP3), CYP2B6 c.516GT (SNP4), and CYP2B6
c.785AG (SNP5). These specific allelic variants confer loss of function
compared to the homozygous wild type.
Univariate analysis was performed for each SNP to test whether there
was an associationwithNVP apparent oral clearance (CL/F); for inclusion
into themodel, the same statistical criteria were applied to the genetic data
as were used for the demographic data outlined above.
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Model evaluation. To assess the final model, a visual predictive check
was performed.One thousand patients were simulated using the fixed and
random effects defined by the final model with the SIMULATION
SUBPROBLEMS option of NONMEM. From the simulated data, a 90%
prediction interval (P5 to P95) was constructed, and observed data from
the original data set were superimposed. At least 90%of data points falling
within the prediction interval was indicative of an adequate model.
RESULTS
Patients. In total, 180 HIV-infected patients were included in the
pharmacokinetic model (101 female). This subset of patients was
selected to represent sex, hypersensitivity, and viral hepatitis phe-
notypes of the larger data set (n 1,117). As this was a substudy
within the larger prospective study, no power calculations were
performed. Median (range) age, weight, BMI, and CD4 cell count
(all at start of ART) and duration of therapy at time of sampling
were 34 years (21 to 62), 54 kg (35 to 94), 20 kg/m2 (15 to 38), 156
cells/mm3 (1 to 812), and 6 weeks (1 to 26), respectively. Twenty-
five patients were hypersensitive (60% female; n 18 rash, n 3
jaundice, n  4 SJS), 3 of whom developed a hypersensitivity
reaction following the first pharmacokinetic sample. Overall, 23
patients were coinfected with hepatitis (hepatitis B virus [HBV],
n 12; HCV, n 5; HBV/HCV, n 6). All patients received the
standard dose of NVP (200 mg twice daily), with the exception of
3 patients whowere in the 2-week induction phase of 200mg once
daily.
Pharmacokinetic sampling. Of the 40 NVP-tolerant patients
in whom rich sampling was performed, 35 also had 1 to 2 addi-
tional random samples drawn. In sparsely sampled patients, an
additional sample was taken if hypersensitivity developed follow-
ing the initial sampling day (n  3). Time postdose ranged be-
tween 0.42 and 28 h; three samples taken 360 h (n 1) and 312 h
(n  2) postdose were undetectable (below the lower limit of
quantification; 0.518 mg/liter) and excluded from the analysis. A
total of 383 samples were included with a median (range) NVP
serum concentration of 5.7 mg/liter (1.2 to 25.5).
Pharmacokinetic and covariate model. A one-compartment
model with first-order absorption best described the data; it was
parameterized by NVPCL/F, apparent volume of distribution (V/
F), and absorption rate constant (ka). Model fit was not signifi-
cantly improved by the sequential addition of sample data from
weeks 1 to 3 (to account for effects of autoinduction) but im-
proved without fixing of ka compared with a fixed value of 1.66
h1 as previously estimated (4) (
OFV, 12.0). In addition to
interindividual variability (IIV) on CL/F, addition of IIV on V/F
or ka or inclusion of an absorption lag time did not improve the
model. Interoccasion variability (IOV) on CL/F significantly im-
proved themodel fit (
OFV,82.5). IIV and IOVwere described
by exponential models, and residual error was described by a pro-
portional model. Inclusion of a bioavailability factor (F1) to ac-
count for poor compliance in the sparse sampling data set did not
improve the fit (
OFV,0.5). The model failed to converge with
inclusion of separate error models for sparse and rich data. NVP
CL/F was described by the equation CL/Fij 1 exp(i ij),
where CL/Fij illustrates NVP CL/F of the ith individual on the jth
occasion, 1 is the population parameter estimate, i is the IIV
assumed to have a mean of zero and variance of 2, and ij is the
IOV assumed to have a mean of zero and variance of 2.
Residual errorwas described asY F (1 ε1), whereY is the
observed NVP concentration, F is the predicted concentration,
and ε1 is the proportional random effects, assumed to have amean
of zero and variance of 1
2.
Pharmacokinetic parameters of the basic model are summa-
rized in Table 1. None of the patient characteristics evaluated,
including experience of HSR, showed a significant association
with NVP CL/F (
OFV of between0.02 and3.1).
Pharmacogenetic analysis. Pharmacogenetic data were miss-
ing for 23, 25, 23, 26, and 33 patients for SNPs 1 to 5, respectively,
due to poor quality of theDNAor genotyping failure. In total, data
for all 5 SNPswere not available for 21 patients, and for another 21
patients, data were missing for either 1 SNP or a combination of 2
SNPs; however, all patients were included. Genotypes were in
Hardy-Weinberg equilibrium.
Allelic frequencies for heterozygote and homozygote mutants
for CYP3A5*6 and CYP3A5*3 were 31.8 and 1.3% and 29.0 and
5.2%, respectively. No homozygote mutants (CC) were observed
for CYP2B6 c.983TC, but the frequency of heterozygotes was
17.2% (TC). Heterozygote and homozygote mutant allelic fre-
quencies for CYP2B6 c.516GT were 48.7% (GT) and 16.2%
(TT), respectively, and those for CYP2B6 c.785AG were 44.2%
(AG) and 15.0% (GG), respectively.
Each genotype was evaluated individually, and a separate ran-
dom effect was included for each genotype and to accommodate
themissingdata as shown in the following:CLCL01GEN1(1
MISS) 2GEN2(1MISS) 3MISS, where CL0 is the typical
value ofNVPCL/F for homozygotewild-type individuals;1,2, and
3 are the absolute changes in NVP CL/F for heterozygotes and ho-
mozygote mutants (heterozygotes only for CYP2B6 c.983TC) and
missing data, respectively, compared to homozygote wild-type pa-
tients; GENi is an indicator variable which takes the value of 1 for
the ith genotype (i.e., GEN1, heterozygotes; GEN2, homozygote
mutants) and otherwise takes the value 0; andMISS is an indicator
variable for missing data, also taking the value of 1 or 0.
TABLE 1 Nevirapine parameter estimates and standard errors obtained
from the basic population pharmacokinetic model and the final
pharmacokinetic/pharmacogenetic model (n 180)a
Parameter (unit)
Basic model Final model
Estimate RSEb (%) Estimate RSEb (%)
CL/F (liters/h) 2.74 3.76 3.02 4.44
V/F (liters) 113 23.2 114 22.8
ka (h
1) 0.569 26.7 0.578 26.1
IIV CL/F (%) 33.5 26.9 33.2 27.4
IOV CL/F (%) 34.9 23.3 31.8 24.2
Covariates





Proportional (%) 13.1 17.0 13.1 17.0
a Abbreviations: CL/F, apparent oral clearance of nevirapine (basic model) or apparent
oral clearance of nevirapine in patients with reference genotype wt983TC/wt or
het516GT (final model); V/F, apparent volume of distribution; ka, absorption rate
constant; IIV, interindividual variability; IOV, interoccasion variability; RSE, relative
standard error; SE, standard error; 1, absolute change in CL/F for CYP2B6
983TT/516TT genotype compared to reference genotype (CYP2B6 983TT/516GG or
GT); 2, absolute change in CL/F for het983TC/wt or het516GT genotype compared to
reference genotype.
b RSE (SEestimate/estimate) 100.
Dickinson et al.











Following univariate analysis, CYP2B6 c.983TC, CYP2B6
c.516GT, and CYP2B6 c.785AG were significantly associated
with NVP CL/F (
OFV, 16.9, 5.6, and 6.4, respectively).
NVP CL/F was reduced by 0.958 liter/h (33.0%) in CYP2B6 983
heterozygotes (TC). The contribution ofCYP2B6 785AG (hetero-
zygote) appeared to be small (increase in CL/F of 0.00207 liter/h,
0.07%), and a decrease in CL/F of 0.641 liter/h (22.9%) was ob-
served for homozygousmutants (GG). A reducedmodel combin-
ing wild type (785AA) and heterozygotes (785AG) produced a
similar result (
OFV, 6.4; decrease in CL/F of 22.9% for ho-
mozygousmutants). NVPCL/Fwas decreased by 7.6% and 19.5%
in CYP2B6 516 heterozygotes (GT) and homozygote mutants
(TT), respectively.
Multiple SNP analysis. Based on the univariate analysis, pair-
wise combinations were evaluated in the model for SNPs with the
most impact on NVP CL/F. Addition of CYP2B6 c.785AG ge-
notypes in the reduced form (i.e., AA and AG combined) into a
model containing CYP2B6 c.983TC significantly improved the
fit (
OFV,6.1). NVP CL/F was reduced by 29.1% and 34.5% in
patients with CYP2B6 983TT/785GG and CYP2B6 983TC/785AA
or AG, respectively. However, following a backwards elimination
step the CYP2B6 c.785AG genotype was no longer significant.
Addition of theCYP2B6 c.516GT SNP to themodel contain-
ing the CYP2B6 c.983TC SNP significantly reduced NVP CL/F
by 5.3%, 25.5%, 34.4%, and 39.5%, respectively, for the combina-
tions CYP2B6 983TT/516GT, CYP2B6 983TT/516TT, CYP2B6
983TC/516GG, and CYP2B6 983TC/516GT, respectively (
OFV,
7.6). The change in NVP CL/F for the patients with CYP2B6
983TT/516GT was small (5.3%) compared to the reference geno-
type (CYP2B6 983TT/516GG), and so the CYP2B6 516GT geno-
types were combined with the reference data (reduced model).
This was still significant (
OFV,7.0). NVP CL/F was decreased
by 23.0% and 35.8% for patients with CYP2B6 983TT/516TT and
CYP2B6 983TC/516GG or GT genotypes, respectively. Following
backwards elimination, CYP2B6 c.516GT was retained in the
model. Diagnostic plots of the final model, represented by popu-
lation predicted nevirapine concentrations versus observed con-
centrations and individualmodel predicted concentrations versus
observed nevirapine concentrations, are shown in Fig. 1, and
model parameters are summarized in Table 1.
Of 383measured concentrations, 24 (6.3%;measured between
0 and 9 h) were below the recommendedminimum effective con-
centration (MEC) for NVP of 3.0 mg/liter (16–18). The concen-
trations corresponded to CYP2B6 983TT/516GG or GT (50.0%),
CYP2B6 983TC/516TT (4.2%), and missing (45.8%) genotypes.
Trough concentrations (Ctrough) (concentrations 12 h postdose)
were not available for any of the patients included in the model
and were therefore predicted for each patient at each occasion (n
219). Median (range) individual predicted trough concentrations
were 5.25mg/liter (0.55 to 23.39), and 22/219 were3.0 mg/liter.
The majority of the concentrations below the MEC corresponded
to CYP2B6 983TT/516GG or GT, and none were CYP2B6 983TC/
516GG or GT genotypes.
Model evaluation. Ninety percent prediction intervals (P5 to
P95) were constructed from 1,000 simulated patients using the
fixed and random effects of the final model containing both SNPs
(CYP2B6 983TC and 516GT), and observed data were super-
imposed. Concentrations were simulated out until 30 h postdose
so as to encompass all observed data (latest sample  28 h post-
dose). The data were simulated so that the distribution of alleles
was identical to that of the original data set. Of 383 observed con-
centrations, 4% were above P95 and 2% were below P5 (Fig. 2),
indicative of an adequate model.
In addition, models containing CYP2B6 c.983TC and CYP2B6
c.516GT separately as covariates were used to simulateNVP con-
centrations in a Caucasian population and a Yoruba population
(n 1,000 per group of individuals) based on the allele distribu-
tions provided by HapMap (http://www.hapmap.org). The Yo-
ruba population from Nigeria was used as the closest available
representation genetically to the Malawian population (Fig. 3)
and has also been used as a comparator group for haplotype dis-
tributions for another cohort ofMalawian patients (19). Based on
the simulations, the 90% prediction intervals were similar be-
tween populations despite the decrease in NVP CL/F for CYP2B6
983TC (33%) and CYP2B6 516TT (20%) compared to wild type
and even though the frequency of mutant alleles was higher in the
African population (frequency of CYP2B6 983TT in the Yoruba
population was included asmissing data as patients in the original
data set did not possess this genotype and, therefore, change in
CL/F compared to wild type could not be determined). The Yo-
ruba and Caucasian populations had similar percentages of sim-
ulated concentrations below the NVP MEC for both SNPs
(CYP2B6 c.983TC, 17% versus 13%; CYP2B6 c.516GT, 15%
versus 13%).
DISCUSSION
We have developed and validated a pharmacokinetic model de-
scribing twice-daily NVP in a population of HIV-infected Mala-
wian adults, which evaluates both demographic covariates and
multiple pharmacogenetic influences. Consistent with previous
reports, CYP2B6 516GT and 983TC polymorphisms were
shown to be associated with NVP exposure (7–10).
These data suggest a lack of any direct relationship between
drug exposure (as measured by CL/F) and development of NVP
FIG 1 Goodness-of-fit plots for the final nevirapine pharmacokinetic-phar-
macogenetic model (n  180 patients) illustrating population predictions of
nevirapine versus observed concentrations (a) and individual predictions of
nevirapine versus observed concentrations (b). The fine line describes the line
of unity, and the bold line describes the line of regression.
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HSR. This is in keeping with the broadly accepted hypothesis that
NVPHSR is idiosyncratic, rather than a concentration-dependent
toxicity. Median individual predictions of CL/F, maximum con-
centrations, and Ctrough for those without and with HSR were
similar (2.9 versus 2.2 liters/h, 6.1 versus 5.8 mg/liter, and 5.2
versus 4.9 mg/liter, respectively). However, the number of pa-
tients with HSR was small compared to the number of NVP-tol-
erant individuals. Studies evaluating a relationship between
plasma exposure of NVP andHSR are rare, and no previous study
has prospectively attempted to look for a concentration-toxicity
relationship in HSR. Formation of reactive intermediate metabo-
lites, such as the hydroxyl metabolite 12-OH NVP (a potential
FIG 2 Nevirapine 90% prediction interval (P5 to P95) for the final model combining CYP2B6 983TC and CYP2B6 516GT genotypes from 1,000 simulated
patients. The simulations were performed with a distribution of genotypes identical to that of the original data set. Observed data were superimposed (n 383
concentrations; n 180 patients).
FIG 3 Nevirapine 90% prediction intervals generated from 1,000 simulated patients using the allelic frequencies of CYP2B6 983TC and CYP2B6 516GT in
the Caucasian population and the Yoruba population (to represent Malawian individuals). (a) CYP2B6 983TC, Yoruba; (b) CYP2B6 983TC, Caucasian; (c)
CYP2B6 516GT, Yoruba; (d) CYP2B6 516GT, Caucasian. The recommended minimum effective concentration (MEC) of nevirapine (3.0 mg/liter) is also
shown (16, 22, 24).
Dickinson et al.











cause of HSR), is likely to be influenced by a number of different
factors such as host genetic susceptibility and environmental fac-
tors, in addition to drug exposure. Gender and CD4 count are
recognized risks for NVP HSR (20), and we have also observed
significant associations with human leukocyte antigen (HLA)-
C*04:01 genotype and predisposition to NVP cutaneous reac-
tions, namely, SJS/TEN, in this cohort (n  117 hypersensitive
versusn 154 tolerant patients) (21).Moreover, a recent study by
Sharma and coworkers provided evidence that 12-OH NVP sul-
fate formed in the skin was responsible for NVP-induced rash
(22).
CYP3A4 and CYP3A5 share 90% sequence homology, and
there is a significant overlap in substrate specificity (23). CYP3A5
polymorphisms may be of importance when considering African
populations and metabolism of NVP, because CYP3A5 is more
commonly expressed in Africans, particularly in comparison to
Caucasians. CYP3A5*3 encodes a truncated, nonfunctional
protein (24). TheCYP3A5*3 allele is at a low frequency in African
populations; however, a recent small study observed an associa-
tion between CYP3A5*3 and NVP exposure (area under the
concentration-time curve from 0 to 12 h [AUC0-12]) in 24 HIV-
infected adults and children from Malawi (19). The association
was evident following correction for CYP2B6 516GT polymor-
phism and age, but surprisingly, CYP3A5*3 correlated with lower
AUC0-12 rather than the expected higher exposure (19).
CYP3A5*3 or indeed CYP3A5*6 did not show a significant rela-
tionship with NVP CL/F in the current cohort of HIV-infected
Malawian patients, but allelic frequencies were similar to those
reported by HapMap for the Yoruba population (present study
versus HapMap: AA, 0.66 versus 0.68; AG, 0.29 versus 0.31; GG,
0.05 versus 0.01) and those observed in the previously published
Malawi study (present study versus previous publication: AA, 0.66
versus 0.50; AG, 0.29 versus 0.50;GG, 0.05 versus 0.0).None of the
patient characteristics investigated, such as weight, sex, and age,
had a significant influence on NVP pharmacokinetic parameters.
The relationship between NVP CL/F and CYP2B6 516GT, al-
though significant, described only 3% of the variability in NVP
CL/F, which is consistent with a population analysis in HIV-in-
fected patients from Cambodia (25). Following a further analysis
of the Cambodian data, additional genetic variants described 11%
of the variability in NVP CL/F (CYP2B6 516GT, CYP2B6
rs7251950, and CYP2B6 rs2279343) (26). Furthermore, Liptrott
and coworkers reported an independent association between a
polymorphism in the efflux transporter ABCC10 (MRP7;
rs2125739), along with CYP2B6 516GT, BMI, and time post-
dose, and NVP plasma concentrations; however, the clinical im-
plications of this relationship are currently unknown (27). Vari-
ability in NVP CL/F from the present study was unremarkable
(30% for interindividual and interoccasion variability); how-
ever, inclusion of other factors that were not recorded, for exam-
ple, other SNPs, may better predict NVP pharmacokinetics.
The homozygous mutant for CYP2B6 983TC (983CC) was
not present in this group ofMalawian patients; however, the pres-
ence of the heterozygote (983TC) in combination with CY2B6
516GG or 516GT resulted in decreased NVP CL/F. Reduced NVP
CL/F under these circumstances is potentially due more to the
influence ofCYP2B6 983TC than to theCYP2B6 516GT poly-
morphism, because individuals who are CYP2B6 983TC can ex-
hibit either partial or full loss of function (internal data). Of 219
model predictedCtrough, 10%were below the recommendedMEC
of 3.0 mg/liter for NVP (16–18). All of these patients possessed
wild-type genotypes for both CYP2B6 983TC and 516GT or
wild-type 983TC with heterozygous 516GT. All patients with
983TC experienced Ctrough above the MEC, suggesting that with
just one mutant allele for this polymorphism, patients may be
more likely to suppress virus, although this remains speculative
without supportive pharmacodynamic data. Choices of pharma-
cokinetic parameters to be used for the MEC threshold and
whether the same cutoffs should be used globally are often de-
bated. NVPMEC is based on studies performedmainly in Cauca-
sian patients, and given the differences in NVP concentrations
often observed between different populations, it is questionable
whether the sameMEC should be applied to African populations;
however, an alternative is not yet available. Viral load measure-
ments were not taken as part of this study, and changes in CD4
count from baseline to study completion (6 months on therapy)
were not monitored. However, of the full cohort of 1,117 patients
recruited and started on NVP-based therapy, 103 patients died
(9%), 3 of which were a result of HSR, and 9% did not complete
the 6-month follow-up due to withdrawal of consent, protocol
violations, transfer to another clinic outside the Blantyre catch-
ment area, or becoming lost to follow-up.
Despite the reduction inNVPCL/FwithCYP2B6 516GT and
983TC SNPs in this cohort, based on simulations with Yoruba
andCaucasian genotype frequencies, the influence at a population
level was minimal. Moreover, similar proportions of Ctrough were
below the recommended NVP MEC for both populations (13 to
17%), although carriage of poor metabolizer mutations was
higher in the simulated African population. Potentially, this could
be a result of the particular genotypes studied here having little
impact onNVP variability, or other factors, or indeed SNPs, could
play a more important role in describing exposure for this com-
pound. Potentially, further genetic studies are warranted to help
identify other SNPs that may be of importance regarding antiret-
roviral pharmacokinetics in African populations. However, indi-
vidualized genetic testing or therapeutic drug monitoring is un-
likely to be widely deployed to guide personalized prescribing in
resource-limited settings.
Our findings indicate that without the availability of individual
gene testing and therapeutic drug monitoring, NVP dosing does
not be need to be adapted on the basis of ethnicity, as this would
not reduce the risk of treatment failure (based on the recom-
mended NVP MEC) or prevent toxicity.
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